Added to YB: 2025-11-12
Pitch date: 2025-11-08
NVO [bullish]
Novo Nordisk A/S
+5.91%
current return
Author Info
Summit Stocks shares weekly in-depth articles on the best stocks and insights into their portfolio. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.4T
Pitch Price
DKK 298.75
Price Target
N/A
Dividend
3.63%
EV/EBITDA
8.96
P/E
13.76
EV/Sales
4.74
Sector
Pharmaceuticals
Category
turnaround
Novo Nordisk: Expectations Can't Get Lower
NVO: New CEO Doustdar refocusing on DTC expansion & oral Wegovy launch early 2026. Q3 rev +5% YoY to 75B DKK but growth stagnating vs Lilly. Lowered 2025 guidance to 8-11% rev growth. Trading 70% off highs at 11.9% FCF yield. Needs only 8% annual FCF growth to justify current price.
Read full article (6 min)